Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$1.2 million.

  • SAB Biotherapeutics' Change in Accured Expenses fell 115.49% to -$287,490 in Q3 2025 from the same period last year, while for Sep 2025 it was -$103,750, marking a year-over-year decrease of 106.44%. This contributed to the annual value of -$1.2 million for FY2024, which is 28.21% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Change in Accured Expenses stood at -$1.2 million for FY2024, which was up 28.21% from -$1.7 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Change in Accured Expenses peaked at $3.4 million during FY2021, and registered a low of -$2.5 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$1.8 million, with a median of -$1.7 million in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 139.99% in 2021, then plummeted by 174.98% in 2022.
  • SAB Biotherapeutics' Change in Accured Expenses (Yearly) stood at $1.4 million in 2020, then soared by 139.99% to $3.4 million in 2021, then tumbled by 174.98% to -$2.5 million in 2022, then surged by 32.43% to -$1.7 million in 2023, then increased by 28.21% to -$1.2 million in 2024.